Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Volumn 60, Issue 14 Suppl 3, 2003, Pages

  Milkovich, Gary ^a   Gibson, Gene ^a  

^a RJM and Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DRUG DERIVATIVE; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; ECONOMICS; HOSPITALIZATION; HUMAN; LENGTH OF STAY; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; HEPARIN; HIRUDINS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; PEPTIDE FRAGMENTS; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; STENTS;

MLCS; MLOWN;

EID: 0142213559     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.suppl_3.s15     Document Type: Review

References (29)